Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide

Shingo Eikawa, Kazuhiro Kakimi, Midori Isobe, Kiyotaka Kuzushima, Immanuel Luescher, Yoshihiro Ohue, Kazuhiro Ikeuchi, Akiko Uenaka, Hiroyoshi Nishikawa, Heiichiro Udono, Mikio Oka, Eiichi Nakayama

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Immunogenicity of a long 20-mer NY-ESO-1f peptide vaccine was evaluated in a lung cancer patient TK-f01, immunized with the peptide with Picibanil OK-432 and Montanide ISA-51. We showed that internalization of the peptide was necessary to present CD8 T-cell epitopes on APC, contrasting with the direct presentation of the short epitope. CD8 T-cell responses restricted to all five HLA class I alleles were induced in the patient after the peptide vaccination. Clonal analysis showed that B*35:01 and B*52:01-restricted CD8 T-cell responses were the two dominant responses. The minimal epitopes recognized by A*24:02, B*35:01, B*52:01 and C*12:02-restricted CD8 T-cell clones were defined and peptide/HLA tetramers were produced. NY-ESO-1 91-101 on A*24:02, NY-ESO-1 92-102 on B*35:01, NY-ESO-1 96-104 on B*52:01 and NY-ESO-1 96-104 on C*12:02 were new epitopes first defined in this study. Identification of the A*24:02 epitope is highly relevant for studying the Japanese population because of its high expression frequency (60%). High affinity CD8 T-cells recognizing tumor cells naturally expressing the epitopes and matched HLA were induced at a significant level. The findings suggest the usefulness of a long 20-mer NY-ESO-1f peptide harboring multiple CD8 T-cell epitopes as an NY-ESO-1 vaccine. Characterization of CD8 T-cell responses in immunomonitoring using peptide/HLA tetramers revealed that multiple CD8 T-cell responses comprised the dominant response. What's new? An antigen called NY-ESO-1 is expressed by a wide range of human cancers, and has shown promise as a cancer vaccine. In this study, the authors studied a peptide derived from that antigen, and analyzed the cellular and molecular mechanisms that allow the peptide to provoke an immune response. They found that the peptide must be internalized by antigen-presenting cells (APCs) in order to yield T-cells that can attack tumours via the NY-ESO-1 antigen. These data increase our understanding of the requirements for an effective therapeutic cancer vaccine. (This section added after initial online publication.)

Original languageEnglish
Pages (from-to)345-354
Number of pages10
JournalInternational Journal of Cancer
Volume132
Issue number2
DOIs
Publication statusPublished - Jan 15 2013

Fingerprint

Immunization
Alleles
T-Lymphocytes
Peptides
Epitopes
Neoplasms
Picibanil
Cancer Vaccines
T-Lymphocyte Epitopes
Antigen-Presenting Cells
Antigens
Subunit Vaccines
Publications
Lung Neoplasms
Vaccination
Vaccines
Clone Cells
Population

Keywords

  • cancer vaccine
  • CD8 T-cell response
  • long peptide
  • NY-ESO-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. / Eikawa, Shingo; Kakimi, Kazuhiro; Isobe, Midori; Kuzushima, Kiyotaka; Luescher, Immanuel; Ohue, Yoshihiro; Ikeuchi, Kazuhiro; Uenaka, Akiko; Nishikawa, Hiroyoshi; Udono, Heiichiro; Oka, Mikio; Nakayama, Eiichi.

In: International Journal of Cancer, Vol. 132, No. 2, 15.01.2013, p. 345-354.

Research output: Contribution to journalArticle

Eikawa, S, Kakimi, K, Isobe, M, Kuzushima, K, Luescher, I, Ohue, Y, Ikeuchi, K, Uenaka, A, Nishikawa, H, Udono, H, Oka, M & Nakayama, E 2013, 'Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide', International Journal of Cancer, vol. 132, no. 2, pp. 345-354. https://doi.org/10.1002/ijc.27682
Eikawa, Shingo ; Kakimi, Kazuhiro ; Isobe, Midori ; Kuzushima, Kiyotaka ; Luescher, Immanuel ; Ohue, Yoshihiro ; Ikeuchi, Kazuhiro ; Uenaka, Akiko ; Nishikawa, Hiroyoshi ; Udono, Heiichiro ; Oka, Mikio ; Nakayama, Eiichi. / Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. In: International Journal of Cancer. 2013 ; Vol. 132, No. 2. pp. 345-354.
@article{77d2b97fbcb04f31a498757831ec036c,
title = "Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide",
abstract = "Immunogenicity of a long 20-mer NY-ESO-1f peptide vaccine was evaluated in a lung cancer patient TK-f01, immunized with the peptide with Picibanil OK-432 and Montanide ISA-51. We showed that internalization of the peptide was necessary to present CD8 T-cell epitopes on APC, contrasting with the direct presentation of the short epitope. CD8 T-cell responses restricted to all five HLA class I alleles were induced in the patient after the peptide vaccination. Clonal analysis showed that B*35:01 and B*52:01-restricted CD8 T-cell responses were the two dominant responses. The minimal epitopes recognized by A*24:02, B*35:01, B*52:01 and C*12:02-restricted CD8 T-cell clones were defined and peptide/HLA tetramers were produced. NY-ESO-1 91-101 on A*24:02, NY-ESO-1 92-102 on B*35:01, NY-ESO-1 96-104 on B*52:01 and NY-ESO-1 96-104 on C*12:02 were new epitopes first defined in this study. Identification of the A*24:02 epitope is highly relevant for studying the Japanese population because of its high expression frequency (60{\%}). High affinity CD8 T-cells recognizing tumor cells naturally expressing the epitopes and matched HLA were induced at a significant level. The findings suggest the usefulness of a long 20-mer NY-ESO-1f peptide harboring multiple CD8 T-cell epitopes as an NY-ESO-1 vaccine. Characterization of CD8 T-cell responses in immunomonitoring using peptide/HLA tetramers revealed that multiple CD8 T-cell responses comprised the dominant response. What's new? An antigen called NY-ESO-1 is expressed by a wide range of human cancers, and has shown promise as a cancer vaccine. In this study, the authors studied a peptide derived from that antigen, and analyzed the cellular and molecular mechanisms that allow the peptide to provoke an immune response. They found that the peptide must be internalized by antigen-presenting cells (APCs) in order to yield T-cells that can attack tumours via the NY-ESO-1 antigen. These data increase our understanding of the requirements for an effective therapeutic cancer vaccine. (This section added after initial online publication.)",
keywords = "cancer vaccine, CD8 T-cell response, long peptide, NY-ESO-1",
author = "Shingo Eikawa and Kazuhiro Kakimi and Midori Isobe and Kiyotaka Kuzushima and Immanuel Luescher and Yoshihiro Ohue and Kazuhiro Ikeuchi and Akiko Uenaka and Hiroyoshi Nishikawa and Heiichiro Udono and Mikio Oka and Eiichi Nakayama",
year = "2013",
month = "1",
day = "15",
doi = "10.1002/ijc.27682",
language = "English",
volume = "132",
pages = "345--354",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide

AU - Eikawa, Shingo

AU - Kakimi, Kazuhiro

AU - Isobe, Midori

AU - Kuzushima, Kiyotaka

AU - Luescher, Immanuel

AU - Ohue, Yoshihiro

AU - Ikeuchi, Kazuhiro

AU - Uenaka, Akiko

AU - Nishikawa, Hiroyoshi

AU - Udono, Heiichiro

AU - Oka, Mikio

AU - Nakayama, Eiichi

PY - 2013/1/15

Y1 - 2013/1/15

N2 - Immunogenicity of a long 20-mer NY-ESO-1f peptide vaccine was evaluated in a lung cancer patient TK-f01, immunized with the peptide with Picibanil OK-432 and Montanide ISA-51. We showed that internalization of the peptide was necessary to present CD8 T-cell epitopes on APC, contrasting with the direct presentation of the short epitope. CD8 T-cell responses restricted to all five HLA class I alleles were induced in the patient after the peptide vaccination. Clonal analysis showed that B*35:01 and B*52:01-restricted CD8 T-cell responses were the two dominant responses. The minimal epitopes recognized by A*24:02, B*35:01, B*52:01 and C*12:02-restricted CD8 T-cell clones were defined and peptide/HLA tetramers were produced. NY-ESO-1 91-101 on A*24:02, NY-ESO-1 92-102 on B*35:01, NY-ESO-1 96-104 on B*52:01 and NY-ESO-1 96-104 on C*12:02 were new epitopes first defined in this study. Identification of the A*24:02 epitope is highly relevant for studying the Japanese population because of its high expression frequency (60%). High affinity CD8 T-cells recognizing tumor cells naturally expressing the epitopes and matched HLA were induced at a significant level. The findings suggest the usefulness of a long 20-mer NY-ESO-1f peptide harboring multiple CD8 T-cell epitopes as an NY-ESO-1 vaccine. Characterization of CD8 T-cell responses in immunomonitoring using peptide/HLA tetramers revealed that multiple CD8 T-cell responses comprised the dominant response. What's new? An antigen called NY-ESO-1 is expressed by a wide range of human cancers, and has shown promise as a cancer vaccine. In this study, the authors studied a peptide derived from that antigen, and analyzed the cellular and molecular mechanisms that allow the peptide to provoke an immune response. They found that the peptide must be internalized by antigen-presenting cells (APCs) in order to yield T-cells that can attack tumours via the NY-ESO-1 antigen. These data increase our understanding of the requirements for an effective therapeutic cancer vaccine. (This section added after initial online publication.)

AB - Immunogenicity of a long 20-mer NY-ESO-1f peptide vaccine was evaluated in a lung cancer patient TK-f01, immunized with the peptide with Picibanil OK-432 and Montanide ISA-51. We showed that internalization of the peptide was necessary to present CD8 T-cell epitopes on APC, contrasting with the direct presentation of the short epitope. CD8 T-cell responses restricted to all five HLA class I alleles were induced in the patient after the peptide vaccination. Clonal analysis showed that B*35:01 and B*52:01-restricted CD8 T-cell responses were the two dominant responses. The minimal epitopes recognized by A*24:02, B*35:01, B*52:01 and C*12:02-restricted CD8 T-cell clones were defined and peptide/HLA tetramers were produced. NY-ESO-1 91-101 on A*24:02, NY-ESO-1 92-102 on B*35:01, NY-ESO-1 96-104 on B*52:01 and NY-ESO-1 96-104 on C*12:02 were new epitopes first defined in this study. Identification of the A*24:02 epitope is highly relevant for studying the Japanese population because of its high expression frequency (60%). High affinity CD8 T-cells recognizing tumor cells naturally expressing the epitopes and matched HLA were induced at a significant level. The findings suggest the usefulness of a long 20-mer NY-ESO-1f peptide harboring multiple CD8 T-cell epitopes as an NY-ESO-1 vaccine. Characterization of CD8 T-cell responses in immunomonitoring using peptide/HLA tetramers revealed that multiple CD8 T-cell responses comprised the dominant response. What's new? An antigen called NY-ESO-1 is expressed by a wide range of human cancers, and has shown promise as a cancer vaccine. In this study, the authors studied a peptide derived from that antigen, and analyzed the cellular and molecular mechanisms that allow the peptide to provoke an immune response. They found that the peptide must be internalized by antigen-presenting cells (APCs) in order to yield T-cells that can attack tumours via the NY-ESO-1 antigen. These data increase our understanding of the requirements for an effective therapeutic cancer vaccine. (This section added after initial online publication.)

KW - cancer vaccine

KW - CD8 T-cell response

KW - long peptide

KW - NY-ESO-1

UR - http://www.scopus.com/inward/record.url?scp=84869508871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869508871&partnerID=8YFLogxK

U2 - 10.1002/ijc.27682

DO - 10.1002/ijc.27682

M3 - Article

VL - 132

SP - 345

EP - 354

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -